Clinical Evaluation and Cost-Effectiveness Analysis of Serum Tumor Markers in Lung Cancer

The detection of serum tumor markers is valuable for the early diagnosis of lung cancer. Tumor markers are frequently used for the management of cancer patients. However, single markers are less efficient but marker combinations increase the cost, which is troublesome for clinics. To find an optimal...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2013-01, Vol.2013 (2013), p.1-7
Main Authors: Li, Xue, Zhang, Nan, Wang, Guoqing, Wang, Rong, Liu, Yunde
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers
Biomarkers, Tumor - blood
Biomarkers, Tumor - economics
Carcinoembryonic antigen
Case-Control Studies
Classification
Cost-Benefit Analysis
Developing countries
Disease
Female
Hospitals
Humans
LDCs
Lung cancer
Lung Neoplasms - blood
Lung Neoplasms - diagnosis
Lung Neoplasms - economics
Lung Neoplasms - pathology
Male
Medical imaging
Middle Aged
Mortality
Neoplasm Proteins - blood
Neoplasm Proteins - economics
ROC Curve
Sensitivity and Specificity
Tumors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The detection of serum tumor markers is valuable for the early diagnosis of lung cancer. Tumor markers are frequently used for the management of cancer patients. However, single markers are less efficient but marker combinations increase the cost, which is troublesome for clinics. To find an optimal serum marker combination panel that benefits the patients and the medical management system as well, four routine lung cancer serum markers (SCCA, NSE, CEA, and CYFRA21-1) were evaluated individually and in combination. Meanwhile, the costs and effects of these markers in clinical practice in China were assessed by cost-effectiveness analysis. As expected, combinations of these tumor markers improved their sensitivity for lung cancer and different combination panels had their own usefulness. NSE + CEA + CYFRA21-1 was the optimal combination panel with highest Youden’s index (0.64), higher sensitivity (75.76%), and specificity (88.57%), which can aid the clinical diagnosis of lung cancer. Nevertheless, the most cost-effective combination was SCCA + CEA, which can be used to screen the high-risk group.
ISSN:2314-6133
2314-6141
DOI:10.1155/2013/195692